Outcomes after virological failure to first-line second-generation INSTI-based therapy in a real-life setting

被引：0
|
作者：
Borjesson, R. Papaioannu [1 ]
Clemente, T. [1 ]
Diotallevi, S. [2 ]
Lolatto, R. [2 ]
Forniti, A. [3 ]
Bottanelli, M. [1 ]
Galli, L. [2 ]
Alberton, F. [1 ]
Muccini, C. [2 ]
Hasson, H. [2 ]
Castagna, A. [2 ]
Spagnuolo, V. [2 ]
机构：
[1] Univ Vita Salute San Raffaele, Milan, Italy
[2] Ist Sci San Raffaele, Infect Dis Unit, Milan, Italy
[3] Univ Florence, Azienda Osped Univ Pisana, Infect Dis Unit, Florence, Italy
来源：
HIV MEDICINE | 2023年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
929
引用
收藏
页码：170 / 172
页数：3
相关论文
共 50 条
  • [41] Nilotinib after imatinib first-line: a real-life longitudinal cohort of patients with chronic myeloid leukaemia in chronic phase
    Cony-Makhoul, Pascale
    Gardembas, Martine
    Coiteux, Valerie
    Carpentier, Nathalie
    Pommier, Cecile
    Violet, Isabelle
    Quittet, Philippe
    Berger, Marc G.
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 180 (03) : 356 - 364
  • [42] First-Line Pharmacotherapies and Survival among Patients Diagnosed with Non-Resectable NSCLC: A Real-Life Setting Study with Gender Prospective
    Spini, Andrea
    Gini, Rosa
    Rosellini, Pietro
    Singier, Allison
    Bellan, Cristiana
    Pascucci, Alessandra
    Leoncini, Lorenzo
    Mathieu, Clement
    Martellucci, Ignazio
    Furiesi, Folco
    Giorgi, Silvano
    Donnini, Sandra
    Roberto, Giuseppe
    Ziche, Marina
    Salvo, Francesco
    CANCERS, 2021, 13 (23)
  • [43] Responses and Outcomes after Second-Line Therapy in Transplant-Eligible Patients with DLBCL Relapse over 1 Year after First-Line Therapy
    Qualls, David A.
    Shah, Gunjan L.
    Shouval, Roni
    Caron, Philip
    David, Kevin A.
    Falchi, Lorenzo
    Ghione, Paola
    Hamlin, Paul A.
    Horwitz, Steven M.
    Intlekofer, Andrew M.
    Johnson, William
    Kumar, Anita
    Lahoud, Oscar Boutros
    Lue, Jennifer Kimberly
    Moskowitz, Alison
    Noy, Ariela
    Palomba, Maria Lia
    Torka, Pallawi
    Vardhana, Santosha A.
    Zelenetz, Andrew D.
    Okwali, Michelle
    Bahrami, Parastoo
    Scordo, Michael
    Lin, Richard J.
    Perales, Miguel-Angel
    Salles, Gilles
    BLOOD, 2023, 142
  • [44] Rabeprazole-amoxicillin dual therapy as first-line treatment forH pylorieradication in special patients: A retrospective, real-life study
    Gao, Wen
    Ye, Hui
    Deng, Xin
    Wang, Chi
    Xu, Ying
    Li, Yixuan
    Zhang, Xuezhi
    Cheng, Hong
    HELICOBACTER, 2020, 25 (05)
  • [45] Real-life data for first-line combination immune- checkpoint inhibition and targeted therapy in patients with melanoma brain metastases
    Hilbers, Marie-Luise
    Dimitriou, Florentia
    Lau, Peter
    Bhave, Prachi
    McArthur, Grant A.
    Zimmer, Lisa
    Kudura, Ken
    Gerard, Camille L.
    Levesque, Mitchell P.
    Michielin, Olivier
    Dummer, Reinhard
    Cheng, Phil F.
    Mangana, Joanna
    EUROPEAN JOURNAL OF CANCER, 2021, 156 : 149 - 163
  • [46] HIV-1 drug resistance at virological failure versus immunological failure among patients failing first-line antiretroviral therapy in a resource-limited setting
    Sungkanuparph, S.
    Win, M. M.
    Kiertiburanakul, S.
    Phonrat, B.
    Maek-a-nantawat, W.
    INTERNATIONAL JOURNAL OF STD & AIDS, 2012, 23 (05) : 316 - 318
  • [47] Treatment options after virological failure of first-line tenofovir-based regimens in South Africa: an analysis by deep sequencing
    Casadella, Maria
    Noguera-Julian, Marc
    Sunpath, Henry
    Gordon, Michelle
    Rodriguez, Cristina
    Parera, Mariona
    Kuritzkes, Daniel R.
    Marconi, Vincent C.
    Paredes, Roger
    AIDS, 2016, 30 (07) : 1137 - 1140
  • [48] Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experience
    Tural, Deniz
    Olmez, Omer Fatih
    Sumbul, Ahmet Taner
    Artac, Mehmet
    Ozhan, Nail
    Akar, Emre
    Cakar, Burcu
    Kostek, Osman
    Paksoy, Nail
    Erman, Mustafa
    Coskun, Hasan Senol
    Selcukbiricik, Fatih
    Keskin, Ozge
    Turkoz, Fatma Paksoy
    Oruc, Kerem
    Bayram, Selami
    Yilmaz, Ugur
    Bilgetekin, Irem
    Yildiz, Birol
    Kilickap, Saadettin
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [49] Atezolizumab in Patients with Metastatic Urothelial Carcinoma Who Have Progressed After First-line Chemotherapy: Results of Real-life Experiences
    Tural, Deniz
    Olmez, Omer Fatih
    Sumbul, Ahmet Taner
    Artac, Mehmet
    Ozhan, Nail
    Akar, Emre
    Cakar, Burcu
    Kostek, Osman
    Ekenel, Meltem
    Erman, Mustafa
    Coskun, Hasan Senol
    Selcukbiricik, Fatih
    Keskin, Ozge
    Turkoz, Fatma Paksoy
    Oruc, Kerem
    Bayram, Selami
    Yglmaz, Ugur
    Bilgetekin, Irem
    Ygldgz, Birol
    Sendur, Mehmet Ali Nahit
    Paksoy, Nail
    Dirican, Ahmet
    Erdem, Dilek
    Selam, Meltem
    Tanrgverdi, Ozgur
    Paydas, Semra
    Urakcg, Zuhat
    Atag, Elif
    Guncan, Sabri
    Urun, Yuksel
    Alkan, Ali
    Kaya, Ali Osman
    Ozyukseler, Deniz Tataroglu
    Taskaynatan, Halil
    Ygldgrgm, Mustafa
    Sonmez, Muge
    Basoglu, Tugba
    Gunduz, Seyda
    Kglgckap, Saadettin
    EUROPEAN UROLOGY FOCUS, 2021, 7 (05): : 1061 - 1066
  • [50] Second-line, anti-VEGF based after first-line, anti-EGFR based treatment in RAS wild-type metastatic colorectal cancer: The multicenter, retrospective, real-life SLAVE study
    Parisi, A.
    Camarda, F.
    Ribelli, M.
    Rossini, D.
    Germani, M.
    Dell'Aquila, E.
    Natoli, C.
    Pietro, D.
    Corsi, D.
    Zurlo, I.
    Lombardi, P.
    Zanaletti, N.
    Giampieri, R.
    Merloni, F.
    Occhipinti, M.
    Marchetti, P.
    Roberto, M.
    Mazzuca, F.
    Ghidini, M.
    Garajova, I.
    Zoratto, F.
    Ficorella, C.
    ANNALS OF ONCOLOGY, 2020, 31 : S144 - S145
12345